BACKGROUND: Surgical resection of bronchopulmonary carcinoid tumors can be curative and remains the primary treatment modality. There are limited data to delineate the optimal extent of resection for this disease. METHODS: A retrospective review of the 3,270 patients diagnosed with typical and atypical carcinoid tumors between 2000 and 2007 in the Surveillance Epidemiology and End Results registry was performed. RESULTS: The mean follow-up period was 46 months (range, 1-95 mo). Overall survival (OS) and disease-specific survival at 5 years was 80% and 90%, respectively. The mean OS was slightly better in the lobectomy group compared with those undergoing sublobar resection (86 vs 83 mo; P = .008). After adjusting for age, this finding was no longer present (P = .513). By using multivariate analysis, sublobar resection was noninferior to lobectomy with regard to disease-specific survival and OS (P < .05). CONCLUSIONS: Compared with lobectomy, sublobar resection is associated with noninferior survival in patients with typical carcinoid of the lung.
BACKGROUND: Surgical resection of bronchopulmonary carcinoid tumors can be curative and remains the primary treatment modality. There are limited data to delineate the optimal extent of resection for this disease. METHODS: A retrospective review of the 3,270 patients diagnosed with typical and atypical carcinoid tumors between 2000 and 2007 in the Surveillance Epidemiology and End Results registry was performed. RESULTS: The mean follow-up period was 46 months (range, 1-95 mo). Overall survival (OS) and disease-specific survival at 5 years was 80% and 90%, respectively. The mean OS was slightly better in the lobectomy group compared with those undergoing sublobar resection (86 vs 83 mo; P = .008). After adjusting for age, this finding was no longer present (P = .513). By using multivariate analysis, sublobar resection was noninferior to lobectomy with regard to disease-specific survival and OS (P < .05). CONCLUSIONS: Compared with lobectomy, sublobar resection is associated with noninferior survival in patients with typical carcinoid of the lung.
Authors: Renee K Dixon; Edward James Britt; Giora A Netzer; Majid Afshar; Allen Burke; Sandy Liu; Jeudy Jean; Nirav G Shah Journal: Lung Date: 2016-08-20 Impact factor: 2.584
Authors: Muhammad Furqan; Yu-Yu Tien; Mary C Schroeder; Kalpaj R Parekh; John Keech; Bryan G Allen; Alexandra Thomas; Jun Zhang; Gerald Clamon; Taher Abu Hejleh Journal: J Thorac Dis Date: 2018-10 Impact factor: 2.895